[1]Lund B, Asberg A, Heyman M, et al. Risk factors for treatment related mortality in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer, 2011, 56(4): 551-559 [2]Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimi-crobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis, 2011, 52(4): e56-93 [3]Barton CD, Waugh LK, Nielsen MJ, et al. Febrile neutropenia in children treated for malignancy. J Infect, 2015, 71(Suppl 1): S27-35 [4]Fu-Chun Kuo, Shih-Min Wang, Ching-Fen Shen, et al. Bloodstream infections in pediatric patients with acute leukemia: Emphasis on gram-negative bacteria infections. J Microbiol Immunol Infect, 2017, 50(4): 507-513 [5]Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis, 2002, 34(6): 730-751 [6]蔡娇阳, 王宁玲, 蒋慧, 等. 儿童急性淋巴细胞白血病2005方案多中心远期临床报告. 中华儿科杂志, 2018, 56 (7): 511-517 [7]张娜, 沈树红, 王宁玲, 等. 年长儿童及青少年急性淋巴细胞白血病多中心临床研究. 中华血液学杂志, 2018, 39(9): 717-723 [8]Özdemir N, Tüysüz G, Çelik N, et al. Febrile neutropenia in children with acute lymphoblastic leukemia: single center experience. Turk Pediatri Ars, 2016, 51(2): 79-86 [9]Reddy R, Pathania S, Kapil A, et al. Review of spectrum and sensitivity of bacterial bloodstream isolates in children with malignancy: A retrospective analysis from a single center. Indian J Cancer, 2014, 51(4): 425-427 [10]El-Mahallawy HA, Hassan SS, El-Wakil M, et al. Increasing antimicrobial resistance monitored in surveillance analysis of blood stream infections in febrile neutropenic pediatric oncology patients. Asian Pac J Cancer Prev, 2015, 16(14): 5691-5695 [11]Johannsen KH, Handrup MM, Lausen B, et al. High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine. Pediatr Blood Cancer, 2013, 60(7): 1154-1160 [12]Berrueco R, Rives S, Català A, et al. Prospective surveillance study of blood stream infections associated with central venous access devices (port-type) in children with acute leukemia: an intervention program. J Pediatr Hematol Oncol, 2013, 35(5): e194-199 [13]Das A, Trehan A, Bansal D. Risk factors for microbiologically-documented infections, mortality and prolonged hospital stay in children with febrile neutroPenia. Indian Pediatr, 2018, 55(10): 859-864 [14]Canbolat Ayhan A, Timur C, Kalaycik O. A retrospective analysis of complications ob-served in children with acute lymphoblastic leukemia during chemotherapy. Minerva Pediatr, 2017, 69(2): 95-105 [15]Blennow O, Ljungman P. The challenge of antibiotic resistance in haematology Patients. Br J Haematol, 2016, 172(4): 497-511 [16]Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer Patients. J Infect, 2014, 68(4): 321-331 [17]Trehan A, Totadri S, Gautam V, et al. Invasive bacterial infections in a pediatric oncology unit in a tertiary care center.Indian J Cancer, 2014, 51(4): 428-431 [18]Kim HS, Park BK, Kim SK, et al. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study. BMC Infect Dis, 2017, 17(1): 500 [19]Ortega M, Marco F, Soriano A, et al. Epidemiology and outcome of bacteraemia in neutropenic patients in a single institution from 1991-2012. Epidemiol Infect, 2015, 143(4): 734-740 [20]Lee JH, Kim SK, Kim SK, et al. Increase in antibiotic-resistant gram-negative bacterial infections in febrile neutropenic children. Infect Chemother, 2016, 48(3): 181-189 [21]Marin M, Gudiol C, Ardanuy C, et al. Bloodstream infections in neutropenic patients with cancer: differences between Patients with haematological malignancies and solid tumours. J Infect, 2014, 69(5): 417-423 |